Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma
Neuro-Oncology Advances · 12.01.2026 · 8 (1)
DOI: 10.1093/noajnl/vdag106 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology Advances, online erschienen am 24.04.2026. Verfasst von Dror Limon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Gray Faculty of Medical and Health Sciences, Tel Aviv University,…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tumor-treating fields (TTFields) have demonstrated efficacy in newly diagnosed glioblastoma (ndGBM) when combined with adjuvant temozolomide (TMZ). Preclinical studies suggest that TTFields enhance the therapeutic effect of radiotherapy (RT), providing a rationale for concurrent administration with radiotherapy (RT). This phase 2 randomized trial evaluated the addition of TTFields to standard RT and TMZ, followed by adjuvant TMZ with TTFields, in patients with ndGBM.
Methods
Patients were randomized prior to chemoradiation to receive RT and TMZ with or without concurrent TTFields, followed by maintenance TMZ with TTFields in both groups. The evaluable cohort, defined as an exploratory analysis, included patients who completed at least 4-weeks of RT (≥40Gy) and TTFields in the experimental arm the primary endpoint, based on the intention-to-treat (ITT) population, was 1-year progression-free survival (PFS12). Secondary endpoints included PFS, overall survival (OS) and safety.
Results
Sixty-six patients were randomized (experimental n = 32; control n = 34). In the ITT population, PFS12 favored the experimental group (28.7% vs 17.3%) but did not reach statistical significance (P = .146). Median PFS was 5.4 vs 4.13 months (P = .14) and median OS was 18.5 vs 16.5 months (P = .95) respectively. In the evaluable cohort (n = 54), PFS12 favored experimental group (37.5% vs 17.3%, P = .06), with a significantly longer median PFS (9.9 vs 4.1 months, P = .016). Median OS favored the experimental group (25.9 vs 16.6 months, P = .308). Treatment was well tolerated, with adverse events similar between groups.
Conclusions
Early integration of TTFields with chemoradiation in ndGBM is safe, feasible. Although the primary endpoint was not met, observed survival trends support further evaluation in larger multicenter trials to confirm the potential benefit of concurrent TTFields with chemoradiation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology Unit, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Oncology, Tel-Aviv Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Neurosurgery, Tel-Aviv Medical Center, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Neurosurgery, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
ORCID-Profile: Rachel Grossman
Zitieren
APA
Limon, D., Bokstein, F., Blumenthal, D. T., Ram, Z., & Grossman, R. (2026). Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag106
Vancouver
Limon D, Bokstein F, Blumenthal DT, Ram Z, Grossman R. Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag106
BibTeX
@article{Limon2026,
author = {Limon, Dror and Bokstein, Felix and Blumenthal, Deborah T and Ram, Zvi and Grossman, Rachel},
title = {Prospective randomized trial of tumor-treating fields with chemoradiation in newly diagnosed glioblastoma},
journal = {Neuro-Oncology Advances},
year = {2026},
volume = {8},
number = {1},
doi = {10.1093/noajnl/vdag106}
}
EUVIMED